EUCTR2015-000990-11-DE进行中（未招募）1 期
A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease - FIDELIO-DKD
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 9,600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Men or women aged 18 years and older. The lower age limit may be higher if legally required in the participating country.
- •- Women of childbearing potential can only be included in the study if a pregnancy test is negative at the Screening Visit and if they agree to use adequate contraception. Adequate contraception is defined as any combination of at least 2 effective methods of birth control, of which at least one is a physical barrier (e.g. condoms with hormonal contraception or implants or combined oral contraceptives, certain intrauterine devices). Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate) or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/mL [for US only: FSH levels > 40 mIU/mL and estradiol < 20 pg/mL] or have had surgical treatment such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy.
- •- Subjects with type 2 diabetes mellitus as defined by the American Diabetes Association
- •- Subjects with a clinical diagnosis of DKD based on either of the following criteria at the Run-in and Screening Visit:
- •Persistent high albuminuria defined as UACR of = 30 mg/g ( = 3.4 mg/mmol) but < 300 mg/g (< 33.9 mg/mmol) in 2 out of 3 first morning void samples and eGFR = 25 but < 60 mL/min/1.73 m2 and presence of diabetic retinopathy in the medical history
- •Persistent very high albuminuria defined as UACR of = 300 mg/g (= 33.9 mg/mmol) in 2 out of 3 first morning void samples and eGFR = 25 but < 75 mL/min/1.73 m2
- •- Prior treatment with ACEIs and ARBs as follows:
- •For at least 4 weeks prior to the Run-in Visit, subjects should be treated with either an ACEI or ARB, or both
- •Starting with the Run in Visit, subjects should be treated with only an ACEI or ARB
- •For at least 4 weeks prior to the Screening Visit, subjects should be treated with the maximum tolerated labeled dose (but not below the minimal labeled dose) of only an ACEI or an ARB (not both) preferably without any adjustments to dose or choice of agent or to any other antihypertensive or antiglycemic treatment
- •- Serum potassium = 4.8 mmol/L at both the Run-in and the Screening Visit
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 4400
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5200
排除标准
- •- Known significant non-diabetic renal disease, including clinically relevant renal artery stenosis
- •- HbA1c > 12% (> 108 mmol/mol) at the Run-in Visit or Screening Visit
- •- Uncontrolled arterial hypertension with mean sitting systolic blood pressure (SBP) = 170 mmHg or mean sitting diastolic blood pressure (DBP) = 110 mmHg at the Run in Visit or mean sitting SBP = 160 mmHg or mean sitting DBP = 100 mmHg at the Screening Visit
- •- Subjects with a clinical diagnosis of chronic heart failure with reduced ejection fraction (HFrEF) and persistent symptoms (New York Heart Association class II-IV) at the Run in Visit (class 1A recommendation for MRAs)
- •- Dialysis for acute renal failure within 12 weeks prior to the Run-in Visit
- •- Renal allograft in place or a scheduled kidney transplant within the next 12 months from the Run in Visit
研究者
相似试验
进行中（未招募）
1 期
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients with Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and are Treated with Insulin (ODYSSEY DM - Insulin)MedDRA version: 20.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861HypercholesterolemiaEUCTR2015-000799-92-DEsanofi-aventis Groupe500
已完成
1 期
A clinical study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of S0597 by intranasal route in healthy male subjectsCTRI/2010/091/001413Sun Pharma Advanced Research Company Ltd40
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, parallel-group phase III clinical study to assess the efficacy and safety of soluble beta 1,3/1,6 glucan (SBG) on oral mucositis in head and neck cancer patients undergoing radiation therapy with or without chemotherapyOral mucositisMedDRA version: 9.1Level: LLTClassification code 10028130Term: Mucositis oralEUCTR2008-005565-54-SKBiotec Pharmacon ASA120
进行中（未招募）
1 期
Proof of concept study of rilzabrutinib in adult participants with moderate-to-severe asthmaAsthmaEUCTR2021-002490-26-ESSanofi aventis recherche et developpement213
进行中（未招募）
1 期
Efficacy and safety of finerenone in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney diseaseEUCTR2015-000990-11-GBBayer AG9,600